The global threat of antimicrobial resistance - The need for standardized surveillance tools to define burden and develop interventions  by Sharland, Mike et al.
JE
T
n
b
A
i
i
M
a
b
A
t
b
a
c
t
y
w
r
i
e
a
l
r
s
h
g
i
J
(
h
0 Pediatr (Rio J). 2015;91(5):410--412
www.jped.com.br
DITORIAL
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nstrumentos  de  vigilância  padronizados  para  deﬁnir  carga  e  desenvolver
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nti-microbial  resistance  (AMR)  is  one  the  biggest  issues
he  medical  community  is  currently  facing,  as  evidenced
y  the  increasing  prevalence  of  pan-resistant  strains.  In
ddition  to  treatment  options,  AMR  also  has  major  ﬁnan-
ial  and  economical  implications.  It  has  been  estimated
hat  up  to  50%  of  antimicrobial  use  is  inappropriate;  each
ear  approximately  2 million  people  in  the  US  are  infected
ith  a  resistant  organism.1 Up  to  23,000  yearly  deaths  are
eportedly  caused  directly  by  such  infections.1 The  situation
s  further  complicated  in  low-income  countries  by  lack  of
ffective  surveillance  systems,  laboratory  diagnostics,  and
ccess  to  appropriate  antimicrobials  in  the  face  of  ﬁnancial
imitations.The  emergence  of  MDR  Gram-negative  bacterial  (GNB)
esistance  is  particularly  of  concern,  especially  in  inten-
ive  care  units  (ICUs)  and  immunocompromised  patients,
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s  there  are  often  limited  treatment  options  avail-
ble  and  second-line  treatments  usually  have  unfavorable
harmacokinetic  and  pharmacodynamics  proﬁles,  which
as  been  linked  to  adverse  outcomes.2 Intensive  care
nits  have  a  disproportionately  high  incidence  of  nosoco-
ial  infections  relative  to  the  number  of  patients,  and
his  incidence  continues  to  rapidly  rise.3,4 For  example,
n  ICUs  in  the  United  States,  the  prevalence  of  MDR
athogens  such  as  vancomycin-resistant  Enterococci  (VRE)
nd  carbapenem-resistant  Acinetobacter  baumannii  has
isen  to  33.3%  and  30%,  respectively.5 Most  of  these  infec-
ions  are  catheter-related  blood  stream  infections  (CRBSI)
nd  ventilator-associated  pneumonia  (VAP).6,7 In  addition,
edical  equipment  is  also  a  risk  factor  for  horizontal  trans-
ission  of  nosocomial  organisms.8 The  high  incidence  of
esistance  may  be  due  to  the  high  burden  of  antimicro-
ial  use  in  this  population,  causing  selective  pressure.
he  European  point  prevalence  survey  of  antimicrobial  use
onducted  by  the  Antibiotic  Resistance  and  Prescribing  in
uropean  Children  (ARPEC)  group  reported  a  signiﬁcantly
igher  prevalence  of  antibiotic  use  in  intensive  care  and
ematology--oncology  wards.9
In  Brazil  and  Latin  America,  the  frequency  of  Gram-
egative  bacilli  in  hospital-acquired  bloodstream  infections
urpasses  those  of  Gram-positive,  with  a  signiﬁcant  propor-
ion  of  multi-resistant  infections.
In  a multicenter  study  evaluating  nosocomial  blood-
tream  infections  (NBSIs)  in  Brazil,  Pereira  et  al.  found
er Editora Ltda. All rights reserved.
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342  clinically  signiﬁcant  episodes  in  pediatric  patients  (≤16
years).  96%  of  BSIs  were  monomicrobial.  Gram-negative
organisms  caused  49.0%  of  these  NBSIs,  Gram-positive  orga-
nisms  caused  42.6%,  and  fungi  caused  8.4%.  The  most
common  pathogens  were  coagulase-negative  staphylococci
(CoNS)  (21.3%),  Klebsiella  spp.  (15.7%),  Staphylococcus
aureus  (10.6%),  and  Acinetobacter  spp.  (9.2%).  The  crude
mortality  was  21.6%  (74  of  342).  45%  of  NBSIs  occurred  in
a  pediatric  or  neonatal  ICU.  The  most  frequent  underlying
conditions  were  malignancy,  in  95  patients  (27.8%).  In  this
study,  the  prevalence  of  antibiotic-resistant  Gram-negative
bacteria  was  very  high,  especially  Pseudomonas  aeruginosa
and  A.  baumannii. Carbapenem-resistance  rates  as  high  as
40%  for  Acinetobacter  spp.  and  23%  for  P.  aeruginosa  were
observed,  among  the  highest  described  in  the  literature  for
the  pediatric  population.10
In  2007,  Arnoni  et  al.  reported  the  Gram-negative  proﬁle
of  infections  in  a  pediatric  center  in  Brazil  and  found  that
47.8%  were  multidrug-resistant,  54.2%  were  Klebsiella  spp.
Extended  spectrum  -lactamase  producers  and  36.4%  were
imipenem-resistant  P.  aeruginosa. The  mortality  rate  was
36.9%  in  the  studied  cases,  and  was  signiﬁcantly  higher  in
the  group  of  patients  with  multidrug  resistant  infections.11
This  retrospective  study  by  Costa  et  al.12 provides  valu-
able  pediatric  data  on  AMR  rates  in  this  vulnerable  cohort
with  hematological  malignancies  in  an  intensive  care  set-
ting,  which  has  not  previously  been  reported.  It  found  a
high  burden  of  GNB  infection  in  this  cohort,  with  MDR-
GNB  accounting  for  just  under  half  of  the  cases.  The  most
common  MDR-GNB  pathogens  were  A.  baumannii  (17%),
Stenotrophomonas  maltophilia  (15%),  Enterobacter  spp.
(15%),  and  K.  pneumonia  (15%).  The  frequency  of  resistance
amongst  these  pathogens  ranged  from  18.5%  up  to  50%.  P.
aeruginosa  was  the  most  commonly  found  non  MDR-GNB
pathogen  (41%).  In  both  MDR-GNB  and  non  MDR-GNB  groups,
bacteria  were  isolated  most  frequently  from  the  tracheal
aspirate,  followed  by  blood  and  urine  cultures.  Solid  CNS
tumors  were  the  most  frequent  underlying  condition  in  both
these  groups.
The  study’s  most  signiﬁcant  ﬁnding  was  the  association  of
MDR-GNB  infection  with  hospital-acquired  infections  (HAIs)
and  hematological  disease  (p  =  0.015,  p  =  0.021,  respec-
tively).  Other  signiﬁcant  ﬁndings  were  the  notably  higher
rate  of  MDR-GNB  infection  in  patients  who  received  inap-
propriate  initial  antibiotic  therapy  or  delayed  treatment.
The  overall  prevalence  rate  of  46.5%  of  MDR-GNB  orga-
nisms  in  the  study  is  similar  to  that  found  in  a  retrospective
observational  study  from  a  tertiary  hospital  in  Rome  (39%).13
Although  the  patient  groups  in  these  studies  were  not
entirely  similar,  they  were  comparable  in  that  86.3%  sub-
jects  had  an  underlying  condition.  However,  the  frequencies
of  MDR,  such  as  Escherichia  coli, Klebsiella  pneumoniae  and
A.  baumannii  (50%,  46.6%,  and  36.4%,  respectively),  were
signiﬁcantly  lower  than  resource-limited  intensive  care  or
sepsis  cohorts.  Le  Doare  et  al.  observed  that  66.8%  of  all  iso-
lates  were  GNB  in  resource  poor  settings;  K.  pneumoniae  was
the  predominant  pathogen,  accounting  for  approximately
half  of  the  isolates  and  demonstrating  the  highest  overall
resistance  (50--84.4%  to  third  generation  cephalosporins).14
Similarly,  Cai  et  al.  reported  Gram-negative  organisms
as  responsible  for  65.5%  cases  of  VAP  in  PICU  patients
from  Wuhan,  China.  MDR  A.  baumannii  was  responsible
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or  more  than  50%  of  these  infections;  over  70%  strains
ere  carbapenem-  and  cephalosporin-resistant.15 A  small
rospective  Thai  study  in  PICU  patients  also  demonstrated
hat  approximately  half  of  HAIs  were  due  to  MDR-GNB  orga-
isms,  in  particular  A.  baumannii  and  Pseudomonas  spp.,
ll  of  which  were  carbapenem-resistant.16 This  study  also
ound  stay  of  more  than  seven  days  in  PICU  to  be  an  indepen-
ent  risk  factor  for  MDR-HAI.16 Several  previous  studies  have
lso  demonstrated  the  association  between  prior  antibiotic
se  and  infection  with  drug-resistant  organisms,  especially
ram-negative  bacteria.17,18 An  association  between  emer-
ence  of  resistant  organisms  and  use  of  particular  antibiotic
gents  more  commonly  has  also  been  found  in  longitudinal
ime-series  analyses.19
Berezin  et  al.  reviewed  GNB  in  PICU  and  neonatal  ICU
NICU)  set-ups  in  Latin  America,20 however,  only  six  of  the  12
ncluded  studies  reported  susceptibility  data,  suggesting  the
eneral  paucity  of  surveillance  data  from  the  region.  One
tudy  reported  64%  of  K.  pneumoniae  isolates  were  resistant
o  third-generation  cephalosporins,  but  all  K.  pneumoniae
nd  80%  of  P.  aeruginosa  were  susceptible  to  carbapenems,
hich  differed  from  the  ﬁndings  of  Costa  et  al.12 In  general,
he  review  found  a  higher  rate  of  HAI  in  children  admitted  to
ICU  in  Latin  America  when  compared  to  similar  European
nd  North  American  settings.  There  was  a  wide  variability
n  frequency  of  GNB,  depending  on  the  region,  although
he  commonest  organisms  were  similar  (i.e.,  K.  pneumo-
iae,  E.  coli, and  P.  aeruginosa), with  only  sporadic  cases  of
cinetobacter  but  with  a  high  level  of  MDR.
Given  the  national  and  regional  variations  of  resistance
atterns,  as  indicated  by  previous  studies,  as  well  as  likeli-
ood  of  admissions  to  such  centers  occurring  from  different
arts  of  the  country,  larger  prevalence  studies  are  required
o  enhance  understanding  of  resistance  patterns.  Long  term
utcome  in  these  patients,  taking  into  account  the  prognosis
f  underlying  malignancies,  would  also  add  to  the  under-
tanding  of  the  implications  of  infection  with  MDR-GNB.
The  WHO  six-point  package,  issued  to  combat  AMR  at
he  World  Health  Day  2011,  emphasized  need  for  ﬁnancial
ommitment,  strengthening  surveillance,  access  to  quality
edicines,  stewardship,  infection  control,  and  promoting
esearch  into  new  ways  of  combating  infectious  diseases.21
he  GARPEC  project  is  one  such  initiative  that  aims  to  pro-
ote  collaborative  research  and  collection  and  sharing  data
etween  participants  at  a  regional  and  global  level  in  order
o  accumulate  an  evidence  base  for  developing  appropri-
te  stewardship  programs  based  on  antibiotic  prescribing
atterns  and  resistance  surveillance  data.  International  col-
aboration  on  standardised  surveillace  efforts  linked  with
vidence  based  interventions  will  be  key  in  overcoming  this
mpending  threat  to  international  child  health.
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